Vanguard Group
MATN

Vanguard Group’s Mateon Therapeutics, Inc. MATN Stock Holding History

Vanguard Group’s Portfolio MATN Stock Details MATN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-787,313
Closed -$489K – 4101
2016
Q3 		$489K Sell
787,313
-2,300
-0.3% -$1.56K ﹤0.01% 3761
2016
Q2 		$553K Buy
+789,613
New +$559K ﹤0.01% 3769

Other funds holding MATN

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Vanguard Group's MATN Position: Q4 2016 in Review

Vanguard Group sold out of Mateon Therapeutics, Inc. (MATN) in Q4 2016, closing a stake of 787,313 shares — an estimated $489K sold.

Vanguard Group first reported a position in MATN in Q2 2016 and held it in 2 quarters. The position peaked at $553K in Q2 2016. 1 fund tracked by Wall St. Rank holds MATN as of Q4 2016.

  • Vanguard Group reported no remaining Mateon Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Vanguard Group sold 787,313 Mateon Therapeutics, Inc. shares in Q4 2016, an estimated $489K.
  • Vanguard Group first reported a position in Mateon Therapeutics, Inc. in Q2 2016 and held it in 2 quarters.
  • Vanguard Group's Mateon Therapeutics, Inc. position peaked at $553K in Q2 2016.
  • 1 fund tracked by Wall St. Rank held Mateon Therapeutics, Inc. as of Q4 2016.

Based on Vanguard Group's 13F filing for Q4 2016, filed 14 Feb 2017.